TriangleDISEASE & TREATMENT SETTING
Xalkori: unresectable recurrent Inflammatory myofibroblastic tumor with ALK Positive, ALK positive
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
1.3 Unresectable, Recurrent, or Refractory ALK-Positive Inflammatory Myofibroblastic Tumor XALKORI is indicated for the treatment of adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive.
Broader topic: Inflammatory Myofibroblastic Tumor
- Source population
- Not part of this definition
- Disease extent
- recurrent
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- unresectable
Biomarkers, prior therapy and derivation
- molecular
- gene
- ALK
- alteration
- Positive
- status
- present
- gene
- ALK
- alteration
- positive
- status
- present
- prior therapy
- derivation status
- source-attested
- derivation note
- Scoped from the FDA approved indication for Xalkori (product label). Only dimensions stated in that wording are part of this definition.
- source wording
- 1.3 Unresectable, Recurrent, or Refractory ALK-Positive Inflammatory Myofibroblastic Tumor XALKORI is indicated for the treatment of adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive.
Study evidence for this setting
Source relationships and population-mapping limitations
- bindings
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice